Get started
REPLIGEN CORPREPLIGEN CORPREPLIGEN CORP

REPLIGEN CORP

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

RGN chart


Full chart

RGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.92 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.13 EUR
Net income (FY)
‪32.25 M‬ EUR
Revenue (FY)
‪572.93 M‬ EUR
Shares float
‪52.13 M‬
Beta (1Y)
0.36

Employees


Employees (FY)
‪1.78 K‬
Change (1Y)
−242 −11.95%
Revenue / Employee (1Y)
‪321.33 K‬ EUR
Net income / Employee (1Y)
‪18.09 K‬ EUR

About Repligen Corporation


Sector
Health Technology
CEO
Olivier Dominique Loeillot
Headquarters
Waltham
Website
repligen.com
Founded
1981
FIGI
BBG000FSG8L3
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RGN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

RGN highest yielding bonds


RGEN5964422
Repligen Corporation 1.0% 15-DEC-2028
Yield to maturity
−0.53%
Maturity date
Dec 15, 2028

Explore more bonds 

Frequently Asked Questions


The current price of RGN is 139.30 EUR — it has decreased by −1.17% in the past 24 hours. Watch REPLIGEN CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange REPLIGEN CORP stocks are traded under the ticker RGN.
RGN stock has fallen by −8.20% compared to the previous week, the month change is a 3.57% rise, over the last year REPLIGEN CORP has showed a −16.29% decrease.
We've gathered analysts' opinions on REPLIGEN CORP future price: according to them, RGN price has a max estimate of 216.33 EUR and a min estimate of 153.83 EUR. Watch RGN chart and read a more detailed REPLIGEN CORP stock forecast: see what analysts think of REPLIGEN CORP and suggest that you do with its stocks.
RGN reached its all-time high on Sep 27, 2021 with the price of 291.38 EUR, and its all-time low was 1.09 EUR and was reached on Jul 26, 2004. View more price dynamics on RGN chart.
See other stocks reaching their highest and lowest prices.
RGN stock is 2.25% volatile and has beta coefficient of 0.36. Track REPLIGEN CORP stock price on the chart and check out the list of the most volatile stocks — is REPLIGEN CORP there?
Today REPLIGEN CORP has the market capitalization of ‪7.92 B‬, it has decreased by −9.49% over the last week.
Yes, you can track REPLIGEN CORP financials in yearly and quarterly reports right on TradingView.
REPLIGEN CORP is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
RGN earnings for the last quarter are 0.39 EUR per share, whereas the estimation was 0.30 EUR resulting in a 28.22% surprise. The estimated earnings for the next quarter are 0.40 EUR per share. See more details about REPLIGEN CORP earnings.
REPLIGEN CORP revenue for the last quarter amounts to ‪135.41 M‬ EUR, despite the estimated figure of ‪137.43 M‬ EUR. In the next quarter, revenue is expected to reach ‪161.20 M‬ EUR.
RGN net income for the last quarter is ‪−587.38 K‬ EUR, while the quarter before that showed ‪5.33 M‬ EUR of net income which accounts for −111.01% change. Track more REPLIGEN CORP financial stats to get the full picture.
No, RGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has ‪1.78 K‬ employees. See our rating of the largest employees — is REPLIGEN CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REPLIGEN CORP EBITDA is ‪104.60 M‬ EUR, and current EBITDA margin is 21.42%. See more stats in REPLIGEN CORP financial statements.
Like other stocks, RGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REPLIGEN CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REPLIGEN CORP technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REPLIGEN CORP stock shows the sell signal. See more of REPLIGEN CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.